69.10 USD
▲+0.10+1.44%
盘后 68.12 0.00%
2026-08-03
市值
$5.77B
市盈率
—
EPS
-0.47
股息率
—
52 周区间
43.18 – 90.87
成交量
1.42M
Beta
0.54
目标价
97.86
52W 低 43.1852W 高 90.87
价格走势
公司简介
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children....